Arnica Tincture Fot the Treatment of Cutaneous Leishmaniasis

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

May 3, 2023

Primary Completion Date

November 2, 2024

Study Completion Date

August 31, 2025

Conditions
Leishmaniasis, Cutaneous
Interventions
DRUG

Arnica Tincture

Arnika tincture is a topical plant-based preparation legally authorized in Colombia and in the countries of the European community, the product of this study is Arnika tinktur Gehrlicher (5249), manufactured by Gehrlicher Pharmazeutische Extrakte GmbH, Germany. According to the European Pharmacopoeia, the solution is a 70% hydroethanolic tincture prepared from the flowers of A. montana L, and composed at least 0.04% of sesquiterpene lactones. Arnica tincture will be applied topically by each participant on all lesions until day 30 or 45, depending on the regimen to be evaluated.

Trial Locations (1)

0004

Program for Research and Control in Tropical Diseases - PECET, Medellín

All Listed Sponsors
collaborator

INNOVATION CORPORATION FOR THE DEVELOPMENT OF PRODUCTS FOR TROPICAL DISEASES (CIDEPRO)

UNKNOWN

lead

Universidad de Antioquia

OTHER